The JI Acurri Cytometers
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bill, J. R.
Right arrow Articles by Fontenot, A. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bill, J. R.
Right arrow Articles by Fontenot, A. P.
The Journal of Immunology, 2005, 175: 7029-7037.
Copyright © 2005 by The American Association of Immunologists

Beryllium Presentation to CD4+ T Cells Is Dependent on a Single Amino Acid Residue of the MHC Class II {beta}-Chain1

Jerome R. Bill*,{dagger}, Douglas G. Mack*, Michael T. Falta*,{dagger}, Lisa A. Maier*,{ddagger},§, Andrew K. Sullivan*, Fenneke G. Joslin*, Allison K. Martin*, Brian M. Freed*,{dagger}, Brian L. Kotzin*,{dagger} and Andrew P. Fontenot2,*,{dagger}

* Department of Medicine, {dagger} Department of Immunology, and {ddagger} Department of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, Denver, CO 80262; and § Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206

Chronic beryllium disease (CBD) is characterized by a CD4+ T cell alveolitis and granulomatous inflammation in the lung. Genetic susceptibility to this disease has been linked with HLA-DP alleles, particularly those possessing a glutamic acid at position 69 (Glu69) of the {beta}-chain. However, 15% of CBD patients do not possess a Glu69-containing HLA-DP allele, suggesting that other MHC class II alleles may be involved in disease susceptibility. In CBD patients without a Glu69-containing HLA-DP allele, an increased frequency of HLA-DR13 alleles has been described, and these alleles possess a glutamic acid at position 71 of the {beta}-chain (which corresponds to position 69 of HLA-DP). Thus, we hypothesized that beryllium presentation to CD4+ T cells was dependent on a glutamic acid residue at the identical position of both HLA-DP and -DR. The results show that HLA-DP Glu69- and HLA-DR Glu71-expressing molecules are capable of inducing beryllium-specific proliferation and IFN-{gamma} expression by lung CD4+ T cells. Using fibroblasts expressing mutated HLA-DP2 and -DR13 molecules, beryllium recognition was dependent on the glutamic acid at position 69 of HLA-DP and 71 of HLA-DR, suggesting a critical role for this amino acid in beryllium presentation to Ag-specific CD4+ T cells. Thus, these results demonstrate that a single amino acid residue of the MHC class II {beta}-chain dictates beryllium presentation and potentially, disease susceptibility.




This article has been cited by other articles:


Home page
J. Leukoc. Biol.Home page
I. G. Luzina, N. W. Todd, A. T. Iacono, and S. P. Atamas
Roles of T lymphocytes in pulmonary fibrosis
J. Leukoc. Biol., February 1, 2008; 83(2): 237 - 244.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. P. Fontenot, T. S. Keizer, M. McCleskey, D. G. Mack, R. Meza-Romero, J. Huan, D. M. Edwards, Y. K. Chou, A. A. Vandenbark, B. Scott, et al.
Recombinant HLA-DP2 Binds Beryllium and Tolerizes Beryllium-Specific Pathogenic CD4+ T Cells
J. Immunol., September 15, 2006; 177(6): 3874 - 3883.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.